Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2 Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination With Other Anti-cancer Agents in Patients With HER2-positive Metastatic Breast Cancer (DESTINY-Breast07)

X
Trial Profile

A Phase 1b/2 Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination With Other Anti-cancer Agents in Patients With HER2-positive Metastatic Breast Cancer (DESTINY-Breast07)

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Durvalumab (Primary) ; Paclitaxel (Primary) ; Pertuzumab (Primary) ; Trastuzumab-deruxtecan (Primary) ; Tucatinib (Primary)
  • Indications Advanced breast cancer; HER2 positive breast cancer; Male breast cancer
  • Focus Adverse reactions
  • Acronyms DB-07; DESTINY-Breast07
  • Sponsors AstraZeneca; AstraZeneca AB
  • Most Recent Events

    • 11 Jun 2024 Planned End Date changed from 2 Jul 2025 to 31 Jan 2025.
    • 04 Jun 2024 Results(n=125) from interim analysis of dose-expansion phase assesing T-DXd monotherapy and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
    • 02 Jun 2024 According to an Astrazeneca media release, data from this study were presented at the American Society of Clinical Oncology Scientific Program.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top